Share on LinkedInShare on LinkedIn

ARTICLE · 19 JANUARY 2015

RCEs And The New USPTO Patent Term Adjustment Rules

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Contributor
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private...

View firm profile
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

On January 9, 2015, the Federal Register published final rules implementing changes to patent term adjustment in view of Novartis v. Lee, which the Federal Circuit decided last January.

United StatesIntellectual Property

On January 9, 2015, the Federal Register published final rules implementing changes to patent term adjustment (PTA) in view of Novartis v. Lee, which the Federal Circuit decided last January. The new rules affect patents where a request for continued examination (RCE) was filed during prosecution. In general, the first new rule, effective January 9, 2015, provides that applicants are entitled to B-Delay between allowance and issuance, and the second new rule, effective March 10, 2015, creates a new type of applicant delay when an RCE is filed after allowance.

As previously discussed by Global IP Matters, Novartis focuses on B-Delay, which occurs, per 35 U.S.C. § 154(b)(1)(B), when the U.S. Patent and Trademark Office (USPTO) fails to issue a patent within three years of an application's actual filing date. Novartis held that the filing of an RCE tolls the running of the B-Delay clock whether or not the RCE was filed within three years of the application's actual

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from